Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.6420
+0.0030 (0.47%)
At close: Apr 24, 2026, 4:00 PM EDT
0.6419
-0.0001 (-0.02%)
After-hours: Apr 24, 2026, 4:00 PM EDT
Barinthus Biotherapeutics Employees
Barinthus Biotherapeutics had 14 employees as of December 31, 2025. The number of employees decreased by 91 or -86.67% compared to the previous year.
Employees
14
Change (1Y)
-91
Growth (1Y)
-86.67%
Revenue / Employee
n/a
Profits / Employee
-$4,744,857
Market Cap
26.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | -91 | -86.67% |
| Dec 31, 2024 | 105 | -25 | -19.23% |
| Dec 31, 2023 | 130 | 23 | 21.50% |
| Dec 31, 2022 | 107 | 35 | 48.61% |
| Dec 31, 2021 | 72 | 24 | 50.00% |
| Mar 31, 2021 | 49 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Quince Therapeutics | 36 |
| Curis | 24 |
| NeuroSense Therapeutics | 17 |
| Serina Therapeutics | 13 |
| Exicure | 8 |
| Neuphoria Therapeutics | 8 |
| Lexaria Bioscience | 7 |
BRNS News
- 6 months ago - ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics - PRNewsWire
- 7 months ago - BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
- 7 months ago - Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - GlobeNewsWire
- 11 months ago - Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025 - Accesswire
- 1 year ago - Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 1 year ago - Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 - Accesswire
- 1 year ago - Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - GlobeNewsWire
- 1 year ago - Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer - GlobeNewsWire